Working… Menu

A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC (SHERLOC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02387216
Recruitment Status : Completed
First Posted : March 12, 2015
Last Update Posted : November 7, 2019
Merrimack Pharmaceuticals
Information provided by (Responsible Party):
Elevation Oncology

Brief Summary:
The purpose of this study is to determine whether the combination of MM-121 plus docetaxel is more effective than docetaxel alone in regards to PFS in patients with heregulin-positive NSCLC.

Condition or disease Intervention/treatment Phase
Non-Small Cell Lung Cancer NSCLC Adenocarcinoma Heregulin Drug: MM-121 Drug: Docetaxel Phase 2

Detailed Description:
This study is a randomized, open-label, international, multi-center, phase 2 study in patients with Heregulin-positive NSCLC histologically classified as adenocarcinoma that have progressed following no more than two systemic therapies for locally advanced or metastatic disease, one of which must have been a platinum containing regimen. All patients will initially be screened for heregulin status. Eligible patients will be randomized to receive MM-121 in combination with docetaxel versus docetaxel alone.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 153 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Intervention Model Description: Randomized, open-label, international, multi-center, Phase 2 study in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: SHERLOC: A Phase 2 Study of MM-121 in Combination With Docetaxel Versus Docetaxel Alone in Patients With Heregulin Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Merrimack Pharmaceuticals Inc.)
Actual Study Start Date : February 1, 2015
Actual Primary Completion Date : December 31, 2018
Actual Study Completion Date : March 15, 2019

Resource links provided by the National Library of Medicine

Drug Information available for: Docetaxel

Arm Intervention/treatment
Experimental: Arm A: Experimental Arm
MM-121 in combination with Docetaxel
Drug: MM-121
Investigational, fully human antibody targeting and inhibiting ErbB3
Other Name: seribantumab

Drug: Docetaxel
approved chemotherapy treatment for NSCLC
Other Name: Taxotere

Active Comparator: Arm B: Comparator Arm
Docetaxel alone
Drug: Docetaxel
approved chemotherapy treatment for NSCLC
Other Name: Taxotere

Primary Outcome Measures :
  1. Progression Free Survival [ Time Frame: Time from randomization to progression ]
    Disease status will be assessed according to RECIST v 1.1

Secondary Outcome Measures :
  1. Overall survival [ Time Frame: Approximately 3 years ]
    Time from randomization to death

  2. Objective Response Rate [ Time Frame: approximately 3 years ]
    Based on RECIST v1.1

  3. Time to Progression [ Time Frame: approximately 3 years ]
    Time from randomization to progression

  4. Rate of adverse events reported with the combination of MM-121 with docetaxel [ Time Frame: approximately 3 years ]
    Adverse events analysis

  5. Pharmacokinetic (PK) parameters of MM-121 in combination with docetaxel and docetaxel when given in combination with MM-121. [ Time Frame: approximately 3 years ]
    Pharmacokinetic (PK) profile of MM-121 when given in combination with docetaxel, and of docetaxel when given in combination with MM-121. PK evaluation will be performed on samples obtained at Week 1 pre-dose and post-dose and at pre-dose at Cycle 2 and beyond to assess pre-treatment trough concentrations of MM-121. The maximum observed concentration (Cmax) will be presented and calculated using non-compartmental analysis. Serum levels of MM-121 will be measured at a central lab using an enzyme-linked immunosorbent assay.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with a diagnosis of cytologically or histologically documented adenocarcinoma of the lung with either metastatic disease (stage IV), Stage IIIB or Stage IIIC disease not amenable to surgery with curative intent
  • Not received more than 2 prior systemic therapies- one of which must have been a platinum based regimen- for primary or recurrent disease
  • Tissue submitted for HRG-biomarker testing
  • ECOG performance status (PS) of 0 or 1

Exclusion Criteria:

  • Known ALK mutation
  • Presence of exon 19 deletion or exon 21 (L858R) substitution of the EGFR gene
  • Received >2 prior systemic anti-cancer drug regimen for locally advanced disease
  • Prior treatment with an anti-ErbB3 antibody
  • CTCAE grade 3 or higher peripheral neuropathy
  • Symptomatic CNS metastases or CNS metastases requiring steroids
  • Any other active malignancy requiring systemic therapy
  • Clinically significant cardiac disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02387216

Layout table for location information
United States, Arizona
Tucson, Arizona, United States, 85715
United States, California
Los Angeles, California, United States, 90033
Santa Rosa, California, United States, 95403
United States, Florida
Tampa, Florida, United States, 33612
United States, Illinois
Chicago, Illinois, United States, 60611
United States, Indiana
Lafayette, Indiana, United States, 47905
United States, Massachusetts
Boston, Massachusetts, United States, 02114
Boston, Massachusetts, United States, 02215
Danvers, Massachusetts, United States, 01923
United States, New York
Bronx, New York, United States, 10461
New York, New York, United States, 10016
United States, Pennsylvania
Philadelphia, Pennsylvania, United States, 19111
Pittsburgh, Pennsylvania, United States, 15224
United States, Tennessee
Nashville, Tennessee, United States, 37203
Nashville, Tennessee, United States, 37232
United States, Virginia
Fairfax, Virginia, United States, 22031
United States, Washington
Seattle, Washington, United States, 98101
Canada, Ontario
Toronto, Ontario, Canada, M5G 2M9
CHI Creteil
Créteil, Paris, France, 94010
Centre Léon Bérard
Lyon cedex 08, Rhône-Alpes, France, 69317
Munchen, Bayern, Germany, 80336
Bad Berka, Germany, 99437
Berlin, Germany, 13353
Frankfurt, Germany, 60488
Oldenburg, Germany, 26121
Budapest, Hungary, H-1121
Miskolc, Hungary, H-3529
Tatabanya, Hungary, H-2800
Badalona, Barcelona, Spain, 08916
Majadahonda, Madrid, Spain, 28222
Barcelona, Spain, 08035
Madrid, Spain, 28007
Madrid, Spain, 28046
Malaga, Spain, 29010
Zaragoza, Spain, 50009
Sponsors and Collaborators
Elevation Oncology
Merrimack Pharmaceuticals
Layout table for investigator information
Study Director: MM-121 Program Medical Director, MD Merrimack Pharmaceuticals
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Elevation Oncology Identifier: NCT02387216    
Other Study ID Numbers: MM-121-01-02-09
First Posted: March 12, 2015    Key Record Dates
Last Update Posted: November 7, 2019
Last Verified: November 2019
Keywords provided by Elevation Oncology:
Non-Small Cell Lung Cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action